Search clinical trials for: Telisotuzumab vedotin

Total 395 results

Jennifer Crombie, MD
Genentech, Inc.

Recruiting

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Lymphoma | Lymphoma, Large B-Cell, Diffuse

United States
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE (BV-ICE)

Hodgkin Disease

France, Belgium
Weill Medical College of Cornell University
Genentech, Inc.

Recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Patrick Reagan
Seagen Inc.

Active, not recruiting

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (BV mini CHP)

Diffuse Large B-Cell Lymphoma

United States
The Lymphoma Academic Research Organisation

Completed

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (BRAPP2)

Hodgkin Lymphoma

France
M.D. Anderson Cancer Center
Seagen Inc.

Terminated

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Leukemia

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Czech Lymphoma Study Group

Not yet recruiting

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL (CLSGMCLPOLA)

Lymphoma, Mantle-Cell

Czechia
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Gastric Cancer
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Massachusetts General Hospital
Seagen Inc.

Completed

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Breast Cancer

China
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (BREACH)

Hodgkin Lymphoma

Netherlands, France, Belgium, Croatia, Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Hyperbilirubinemia

United States
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Hoffmann-La Roche
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Bladder Cancer | Urothelial Carcinoma

United States, Spain, Korea, Republic of, United Kingdom, Taiwan, France, Greece
Millennium Pharmaceuticals, Inc.
Seagen Inc.

Completed

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA)

Mycosis Fungoides | Cutaneous T-Cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, France, Italy, United Kingdom, Spain, Switzerland, Brazil, Austria, Belgium, Germany, Poland, Australia
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash

Acne Vulgaris

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Acute Myeloid Leukemia | Leukemia | AML

United States
University of Cologne

Active, not recruiting

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (B-CAP)

Hodgkin Lymphoma

Germany
Massachusetts General Hospital

Completed

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Acute Myelogenous Leukemia

United States
Marjolein Spiering
Millennium: The Takeda Oncology Company

Unknown

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Hodgkin Lymphoma | Relapse | Refractory

Netherlands, France, Denmark, United Kingdom
City of Hope Medical Center

Withdrawn

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Sezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
St. Jude Children's Research Hospital
Seagen Inc.

Active, not recruiting

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma

United States
Mitchell Cairo

Completed

Brentuximab for Newly Diagnosed Hodgkin Disease

Hodgkin Lymphoma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; H. Lee Moffitt... and other collaborators

Completed

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements

United States
Dr. J. Curtis Nickel
University of California, Los Angeles; The Cleveland Clinic

Terminated

JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Benign Prostatic Hyperplasia | Chronic Prostatitis

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Malignant Mesothelioma | CD30-Positive Neoplastic Cells Present

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B-Cell Lymphoma | DLBCL

Poland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China
Hoffmann-La Roche

Recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

Belgium, Korea, Republic of, Australia, China, Japan, United States, Italy, Spain, Taiwan, United Kingdom, France, Mexico, Poland, Germany, Turkey, Brazil, Argentina, Denmark, Canada
Takeda

Recruiting

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Lymphoma

China
University of Rochester
Genentech, Inc.

Recruiting

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Lymphoma, B-Cell | DLBCL

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Neoplasms | Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin | Carcinomas

United States
MerLion Pharmaceuticals GmbH

Completed

Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Healthy

United Kingdom
Karyopharm Therapeutics Inc

Suspended

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.

Withdrawn

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Recurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated T-Cell Lymphoma | Recurrent Follicular T-Cell Lymphoma | Recurrent Hepatosplenic T-Cell Lymphoma | Recurrent... and other conditions

United States
NCIC Clinical Trials Group
National Cancer Institute (NCI); Southwest Oncology Group; North Central Cancer...

Completed

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Breast Cancer | Osteoporosis

Canada
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann... and other conditions

United States
European Organisation for Research and Treatment...

Active, not recruiting

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA)

Advanced Hodgkin Lymphoma

Belgium, Spain, Netherlands, Denmark, Poland, Portugal, Slovakia
R-Pharm

Completed

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Metastatic Breast Cancer

Italy, United Kingdom, United States, France, Spain
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Refractory Primary Mediastinal (Thymic)... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Relapsed Classic Hodgkin Lymphoma

United States
John Reneau

Active, not recruiting

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Classic Hodgkin Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...
Millennium Pharmaceuticals, Inc.

Completed

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

CLASSICAL HODGKIN LYMPHOMA

Spain

Search clinical trials for: Telisotuzumab vedotin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations